Middle Age muScle Krill Study (MASK)

April 27, 2026 updated by: Stuart Gray, University of Glasgow

The Effect of Krill Oil Supplementation on Muscle Function and Mass in Middle-aged Adults: A Randomised Controlled Trial

This study will determine the effect of 6 months of supplementation with krill oil on muscle strength and mass in middle-aged adults. The study hypothesis is that krill oil supplementation will increase muscle strength and mass in middle-aged adults.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Be 35-60 years old
  • Have a BMI of less than 35kg/m2

Exclusion Criteria:

  • People with diabetes, severe cardiovascular disease, seizure disorders, uncontrolled hypertension (>150/90mmHg at baseline measurement), cancer or cancer that has been in remission <5 years, ambulatory impairments which would limit the ability to perform assessments of muscle function, dementia, on anticoagulant therapy, and/or taking medication known to affect muscle (e.g., steroids).
  • People who have allergies to seafood, and/or regular consumption of more than 1 portion of oily fish per week.
  • People who perform regular (>1 day/week) resistance exercise training.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Krill oil 4g/day for 24 weeks
Superba krill oil
Placebo Comparator: Placebo
Vegetable oil 4g/day for 24 weeks
Mixed vegetable oil

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in knee extensor maximal isometric torque ( MVC)
Time Frame: Change from baseline to 24 weeks
Knee extensor maximal isometric torque measured during a maximal voluntary contraction
Change from baseline to 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in fat mass
Time Frame: Change from baseline to 24 weeks
Whole body fat mass measured by measured via bio-electrical impedance
Change from baseline to 24 weeks
Change in lean mass
Time Frame: Change from baseline to 24 weeks
Whole body lean mass measured by measured via bio-electrical impedance
Change from baseline to 24 weeks
Change in omega-3 levels
Time Frame: Change from baseline to 24 weeks
Red blood cell omega-3 levels
Change from baseline to 24 weeks
Change in Grip strength
Time Frame: Change from baseline to 24 weeks
Grip strength measured with a hand held dynamometer
Change from baseline to 24 weeks
Change in Muscle thickness
Time Frame: Change from baseline to 24 weeks
Vastus lateralis muscle thickness measured by ultrasound
Change from baseline to 24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in systemic inflammation
Time Frame: Change from baseline to 24 weeks
Plasma levels of C-reactive protein, IL-1, IL-6, IL-8, IL-10, and TNF-α
Change from baseline to 24 weeks
Change in muscle inflammation
Time Frame: Change from baseline to 24 weeks
Muscle total protein levels of TNF-α, IL-1β, IL-6, IL-8, MCP-1 and total and phosphorylated levels of NFκB, JNK1/2 and STAT3
Change from baseline to 24 weeks
Change in muscle anabolic signalling
Time Frame: Change from baseline to 24 weeks
Muscle total and phosphorylated protein levels of mTOR, IRS-1, Akt, 4EBP-1, p70S6K, RPS6, FOXO-1, GSK3β and total protein levels of MAFBx and MURF-1
Change from baseline to 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2023

Primary Completion (Actual)

October 1, 2025

Study Completion (Actual)

October 1, 2025

Study Registration Dates

First Submitted

August 16, 2023

First Submitted That Met QC Criteria

August 16, 2023

First Posted (Actual)

August 22, 2023

Study Record Updates

Last Update Posted (Actual)

April 29, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on Vegetable oil

Subscribe